-
Product Insights
NewLikelihood of Approval Analysis for Drug Toxicity
Overview How likely is it that the drugs in Drug Toxicity will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Drug Toxicity Overview Drug toxicity' can be defined as a diverse array...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Atuzabrutinib in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atuzabrutinib in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atuzabrutinib in Atopic Dermatitis (Atopic Eczema) Drug Details: Atuzabrutinib (PRN-473)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YPEG-Somatropin in Idiopathic Short Stature
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YPEG-Somatropin in Idiopathic Short Stature report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YPEG-Somatropin in Idiopathic Short Stature Drug Details: YPEG-somatropin is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YPEG-Somatropin in Turner Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YPEG-Somatropin in Turner Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YPEG-Somatropin in Turner Syndrome Drug Details: YPEG-somatropin is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Rilzabrutinib in Chronic Urticaria Or Hives
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rilzabrutinib in Chronic Urticaria Or Hives report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rilzabrutinib in Chronic Urticaria Or Hives Drug Details: Rilzabrutinib (PRN-1008)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Eftozanermin Alfa in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eftozanermin Alfa in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eftozanermin Alfa in Relapsed Multiple Myeloma Drug Details: Eftozanermin alfa...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Eftozanermin Alfa in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eftozanermin Alfa in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eftozanermin Alfa in Diffuse Large B-Cell Lymphoma Drug Details:...